# Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

> **NCT06929325** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 312 (estimated)

## Conditions studied

- HR+/HER2- Advanced/Metastatic Breast Cancer

## Interventions

- **DRUG:** Sirolimus for Injection (Albumin-bound)
- **DRUG:** Fulvestrant Injection
- **DRUG:** Placebo for Sirolimus for Injection (Albumin-bound)

## Key facts

- **NCT ID:** NCT06929325
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2026-10
- **Final completion:** 2027-12
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929325, "Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06929325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*